123 related articles for article (PubMed ID: 31774882)
1. Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237.
Tayyar Y; Shiels R; Bulmer AC; Lam AK; Clarke D; Idris A; McMillan NA
PLoS One; 2019; 14(11):e0225774. PubMed ID: 31774882
[TBL] [Abstract][Full Text] [Related]
2. Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.
Gabrielli B; Bokhari F; Ranall MV; Oo ZY; Stevenson AJ; Wang W; Murrell M; Shaikh M; Fallaha S; Clarke D; Kelly M; Sedelies K; Christensen M; McKee S; Leggatt G; Leo P; Skalamera D; Soyer HP; Gonda TJ; McMillan NA
Mol Cancer Ther; 2015 Dec; 14(12):2753-61. PubMed ID: 26516156
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.
Martin D; Fallaha S; Proctor M; Stevenson A; Perrin L; McMillan N; Gabrielli B
Mol Cancer Ther; 2017 Sep; 16(9):1934-1941. PubMed ID: 28522591
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ
Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
7. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
8. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
9. Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Huck JJ; Zhang M; Mettetal J; Chakravarty A; Venkatakrishnan K; Zhou X; Kleinfield R; Hyer ML; Kannan K; Shinde V; Dorner A; Manfredi MG; Shyu WC; Ecsedy JA
Mol Cancer Ther; 2014 Sep; 13(9):2170-83. PubMed ID: 24980948
[TBL] [Abstract][Full Text] [Related]
10. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
12. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
14. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
Tentler JJ; Ionkina AA; Tan AC; Newton TP; Pitts TM; Glogowska MJ; Kabos P; Sartorius CA; Sullivan KD; Espinosa JM; Eckhardt SG; Diamond JR
Mol Cancer Ther; 2015 May; 14(5):1117-29. PubMed ID: 25758253
[TBL] [Abstract][Full Text] [Related]
15. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
[TBL] [Abstract][Full Text] [Related]
16. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
17. The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Hong X; O'Donnell JP; Salazar CR; Van Brocklyn JR; Barnett KD; Pearl DK; deCarvalho AC; Ecsedy JA; Brown SL; Mikkelsen T; Lehman NL
Cancer Chemother Pharmacol; 2014 May; 73(5):983-90. PubMed ID: 24627220
[TBL] [Abstract][Full Text] [Related]
18. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
[TBL] [Abstract][Full Text] [Related]
19. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
20. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
